Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01723202
Recruitment Status : Active, not recruiting
First Posted : November 7, 2012
Last Update Posted : January 30, 2017
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Manisha Shah, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 31, 2017
  Estimated Study Completion Date : December 31, 2019